glp 1 glucagon dual receptor agonist Effects, working principles and target tissues of agonists GLP-1 Agonists: Dual Benefits for
Description
Glucagon-like peptide-1 infusion must be maintained for 24 hours/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
Despite this long clinical history, widespread public awareness only emerged recently due to expanded weight-loss applications and celebrity discussions, creating the illusion that these are brand-new treatments rather than established medications with proven track records
Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease
Beyond obesity, the emergence of effective oral GLP-1s also highlights opportunities for a broader platform
doi: 10.2337/db14-0302 56 ChangCCLinTCHoHLKuoCYLiHHKorolenkoTAet al
MicroRNAs in Obesity-Associated Disorders: The Role of Exercise Training
